Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in early Type 1 Diabetes
NCT06524960Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in type 1 diabetes mellitus (T1D), sponsored by City of Hope. Started May 2025; status: recruiting.
02
Drugs
denosumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06524960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524960.